Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMCRNASDAQ:KNSANASDAQ:MIRMNASDAQ:OCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMCRImmunocore$32.84+4.7%$32.10$23.15▼$41.54$1.65B0.83348,741 shs428,947 shsKNSAKiniksa Pharmaceuticals International$27.24-1.6%$26.94$17.38▼$30.69$1.99B0.06549,630 shs701,980 shsMIRMMirum Pharmaceuticals$48.39-4.9%$45.72$33.45▼$54.23$2.40B0.95465,682 shs743,618 shsOCSOculis$18.96-2.3%$18.79$10.79▼$23.08$827.79M0.3545,214 shs30,318 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMCRImmunocore+0.84%+0.84%-14.00%+9.61%-7.41%KNSAKiniksa Pharmaceuticals International-1.32%-3.66%+0.87%+27.10%+48.21%MIRMMirum Pharmaceuticals-0.39%+1.21%+14.77%+15.55%+48.84%OCSOculis+0.31%-1.22%-0.46%+4.02%+62.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMCRImmunocore2.453 of 5 stars4.30.00.00.02.52.50.0KNSAKiniksa Pharmaceuticals International3.5524 of 5 stars3.54.00.00.02.73.30.6MIRMMirum Pharmaceuticals3.6439 of 5 stars3.60.00.04.21.61.70.6OCSOculis2.1774 of 5 stars3.53.00.00.02.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMCRImmunocore 2.55Moderate Buy$58.8979.32% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$38.8042.44% UpsideMIRMMirum Pharmaceuticals 3.13Buy$65.5035.36% UpsideOCSOculis 3.00Buy$35.3386.36% UpsideCurrent Analyst Ratings BreakdownLatest OCS, MIRM, KNSA, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.005/27/2025IMCRImmunocoreDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.005/19/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$73.005/13/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy5/13/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.005/9/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$74.00 ➝ $76.005/9/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$28.00 ➝ $33.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.004/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/17/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $32.004/17/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMCRImmunocore$310.20M5.32N/AN/A$7.20 per share4.56KNSAKiniksa Pharmaceuticals International$423.24M4.70N/AN/A$6.60 per share4.13MIRMMirum Pharmaceuticals$336.89M7.11N/AN/A$4.70 per share10.30OCSOculis$780K1,061.27N/AN/A$1.91 per share9.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMCRImmunocore-$51.09M-$0.43N/AN/AN/A-6.48%-5.86%-2.09%8/6/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M-$0.25N/A108.96N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)MIRMMirum Pharmaceuticals-$87.94M-$1.61N/AN/AN/A-20.39%-33.63%-11.50%8/6/2025 (Estimated)OCSOculis-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/19/2025 (Estimated)Latest OCS, MIRM, KNSA, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/22/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.08N/AN/AN/AN/AN/A5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million5/8/2025Q1 2025OCSOculis-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals International$0.02$0.11+$0.09$0.11$128.35 million$137.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMCRImmunocoreN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMCRImmunocore1.036.366.31KNSAKiniksa Pharmaceuticals InternationalN/A3.663.43MIRMMirum Pharmaceuticals1.323.223.04OCSOculisN/A4.794.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMCRImmunocore84.50%KNSAKiniksa Pharmaceuticals International53.95%MIRMMirum PharmaceuticalsN/AOCSOculis22.30%Insider OwnershipCompanyInsider OwnershipIMCRImmunocore10.40%KNSAKiniksa Pharmaceuticals International53.48%MIRMMirum Pharmaceuticals22.87%OCSOculisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMCRImmunocore32050.23 million45.01 millionOptionableKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableMIRMMirum Pharmaceuticals14049.53 million38.21 millionOptionableOCSOculis243.66 millionN/ANot OptionableOCS, MIRM, KNSA, and IMCR HeadlinesRecent News About These CompaniesOculis Holding AG (OCS) - Yahoo FinanceJune 28 at 2:36 PM | sg.finance.yahoo.comOculis Holding AG (NASDAQ:OCS) Sees Large Increase in Short InterestJune 17, 2025 | marketbeat.comLeerink Partnrs Forecasts Oculis' Q2 Earnings (NASDAQ:OCS)June 9, 2025 | marketbeat.comOculis Publishes Results of 2025 Annual General MeetingJune 5, 2025 | globenewswire.comOculis Publishes Results of 2025 Annual General MeetingJune 5, 2025 | globenewswire.comCitadel Advisors LLC Buys Shares of 22,911 Oculis Holding AG (NASDAQ:OCS)June 4, 2025 | marketbeat.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesJune 3, 2025 | globenewswire.comOculis to Participate in Upcoming June Investor ConferencesJune 3, 2025 | markets.businessinsider.comOculis Holding AG Announces Participation in Upcoming Investor Conferences in June 2025June 3, 2025 | quiverquant.comQOculis to Participate in Upcoming June Investor ConferencesJune 3, 2025 | globenewswire.comOculis to Participate in Upcoming June Investor ConferencesJune 3, 2025 | globenewswire.comOculis Holding AG: Oculis Reports Q1 Financial Results and Provides Company UpdateMay 11, 2025 | finanznachrichten.deOculis Publishes Invitation to the Annual General MeetingMay 9, 2025 | globenewswire.comOculis Publishes Invitation to the Annual General MeetingMay 9, 2025 | globenewswire.comOculis posts widening quarterly loss as R&D spend climbsMay 9, 2025 | thepharmaletter.comTOculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comOculis Reports Q1 Financial Results and Provides Company UpdateMay 8, 2025 | globenewswire.comOculis Reports Q1 2025 Financial Results and Provides Company UpdateMay 8, 2025 | globenewswire.comEarnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to DeclineMay 7, 2025 | zacks.comOculis to Present at Upcoming May Investor ConferencesMay 7, 2025 | globenewswire.comOculis to Present at Upcoming May Investor ConferencesMay 7, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCS, MIRM, KNSA, and IMCR Company DescriptionsImmunocore NASDAQ:IMCR$32.84 +1.46 (+4.65%) Closing price 04:00 PM EasternExtended Trading$33.70 +0.86 (+2.62%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Kiniksa Pharmaceuticals International NASDAQ:KNSA$27.24 -0.43 (-1.55%) Closing price 04:00 PM EasternExtended Trading$27.26 +0.02 (+0.06%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Mirum Pharmaceuticals NASDAQ:MIRM$48.39 -2.50 (-4.91%) Closing price 04:00 PM EasternExtended Trading$48.95 +0.56 (+1.16%) As of 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Oculis NASDAQ:OCS$18.94 -0.47 (-2.42%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
